“When Binh Nguyen, then a graduate student in biomedical engineering at the University of Toronto, was working in the renal engineering department of a local hospital, he was struck by what he felt was a suboptimal setup for dialysis treatment,” writes Jordana Dixon in “Health startup helps patients become more independent,” for the Globe and Mail on April 13, 2015.
eQOL Inc. is a University of Toronto and MaRS Innovation start-up company that participated in and graduated from the University of Toronto Early-Stage Technology (UTEST) program’s second cohort.
Taking these complications into consideration, Mr. Nguyen envisioned an all-encompassing lateral system that would optimize the process of in-home dialysis utilizing technology, but most importantly, improving patient experience.
Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool
TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy.
The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck as a clinical tool that gives clinicians rapid, improved transparency to determine if breast cancer tumors are responding to chemotherapy.
WaveCheck is a clinical technique invented, refined and tested by Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook’s Odette Cancer Centre, and Michael C. Kolios, professor of Physics and associate dean, Research and Graduate Studies, in Ryerson University’s Faculty of Science. Their technology uses ultrasound to visually demonstrate whether chemotherapy is destroying a breast cancer tumour at the beginning of chemotherapy treatment in as little as one week. If applied to the clinic, this knowledge has the power to transform patient experience, since existing breast cancer patients typically wait until the end of treatment, anywhere from four to six months, to know if their tumor has responded.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology shows promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.
The agreement leverages GE Healthcare’s extensive ultrasound technology and market expertise in bringing new ultrasound innovations to global hospitals and clinics with Sunnybrook’s leadership in oncology research and cancer care through the Odette Cancer Centre.
VitalHub Chart has been named to Apple’s list of top 80 apps for doctors, nurses, patients and healthcare professionals in the “EMR and patient monitoring” category.
Here’s a description of the app, which is made by Toronto-based VitalHub Corp., from the Apple list curators:
“VitalHub Chart puts patient data at your fingertips. You can access the information you need any time, anywhere there is WiFi or cellular service. No more waiting for a free desktop, hunting for a workstation on wheels, or carrying printouts on rounds.”
“When Binh Nguyen, then a graduate student in biomedical engineering at the University of Toronto, was working in the renal engineering department of a local hospital, he was struck by what he felt was a suboptimal setup for dialysis treatment,” writes Jordana Dixon in “Health startup helps patients become more independent,” for the Globe and Mail on April 13, 2015.
